---
schema_version: "secwatch.filing_event.v1"
accession: "0001326190-24-000016"
form_type: "8-K"
ticker: "ALT"
cik: "0001326190"
company_name: "Altimmune, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:06:44.178878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Altimmune reports Q1 2024 net loss $24.4M; cash $182.1M; pemvidutide milestones on track

## Summary
- Net loss $24.4M ($0.34/share) vs $20.1M ($0.40) in Q1 2023; R&D expense $21.5M on pemvidutide and HepTcell winddown.
- Cash, equivalents & short-term investments $182.1M as of March 31, 2024.
- Phase 2b MASH trial (IMPACT) enrollment ongoing; top-line results expected Q1 2025.
- End-of-Phase 2 FDA meeting for pemvidutide obesity program expected late Q3 2024.
- MOMENTUM Phase 2 data showed 74.5% weight loss from fat, 25.5% from lean mass; visceral fat preferentially reduced.

## SEC filing metadata
- accession: 0001326190-24-000016
- form_type: 8-K
- ticker: ALT
- cik: 0001326190
- company_name: Altimmune, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/0001326190-24-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/alt-20240509x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001326190-24-000016
- JSON: https://secwatch.observer/filing/0001326190-24-000016.json
- Plain text: https://secwatch.observer/filing/0001326190-24-000016.txt

## Key facts
- Earnings Releases
  Altimmune, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, EPS $0.34 net loss per share.
  - Period: the first quarter ended March 31, 2024
  - Net income: Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share
  - EPS: $0.34 net loss per share
  - Result: reported results
  source text: ● Net loss for the three months ended March 31, 2024 was $24.4 million, or $0.34 net loss per share, compared to a net loss of $20.1 million, or $0.40 net loss per share, in the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1326190/000132619024000016/0001326190-24-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.